StockData
Compugen Ltd logo

Compugen Ltd (CGEN) company profile

CGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Mar 2, 2026Score 12/30
$2.02−0.02 (-0.98%)

Close on Nov 17, 2026Market cap $191.00MP/E 5.3Yield –

About Compugen

Biological Products, (No Diagnostic Substances), SIC 2836

Compugen Ltd. is a clinical-stage biotechnology company that discovers and develops therapeutic candidates for cancer immunotherapy and immuno-oncology. The company operates in a single operating segment and utilizes an artificial intelligence and machine learning discovery platform called Unigen to identify novel drug targets. Its primary therapeutic pipeline programs include COM701, COM902, GS-0321, and rilvegostomig, a bispecific antibody developed with a partner. Compugen collaborates with and licenses its therapeutic assets to major pharmaceutical and biotechnology companies, including AstraZeneca and Gilead Sciences.

The company maintains its executive headquarters in Holon, Israel, and conducts business operations through its Israeli parent entity and its wholly owned subsidiary, Compugen USA, Inc. Compugen carries out research, development, and partnering activities with operations and commercial counterparties spanning Israel, the United States, and the United Kingdom. Its operational footprint includes specialized research laboratory facilities, computer equipment, and office infrastructure supporting its internal scientific staff and management team.

Summary of the business section of Compugen's latest annual report, written by StockData.

Company profile

Company

Legal name
Compugen Ltd
Headquarters
Holon, L3
Address
26 Harokmim Street, Building D 5885849
Phone
011-972-3-765-8585
Website
cgen.com
Employees
2, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
L3
Fiscal year ends
December 31
Auditor
KOST FORER GABBAY & KASIERER, Tel-Aviv, Israel

Stock & identifiers

Ticker
CGEN
Exchange
Nasdaq
IPO date
Aug 11, 2000
Shares outstanding
95M, Dec 31, 2025
Filer category
Accelerated filer
SEC CIK
1119774
FIGI
BBG000B9ZLB0
Share class FIGI
BBG001S5PQC7
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Eran OphirPresident and CEO, Director11,375
Pierre FerreChief Operating Officer–
Michelle MahlerChief Medical Officer36,625
Zurit LevineSVP, Business Development47,375
David SilbermanChief Financial Officer55,000
Russo Sharon KredoSVP, Research & Discovery37,500
Anat Cohen-DayagDirector108,622
Eran PerryDirector17,500
Mathias HukkelhovenDirector17,500
Gilead HalevyDirector18,907
Savitzky Kinneret LivnatDirector20,850
Sanford S. ZweifachDirector20,180
Michele HolcombDirector15,000

Employees

Headcount reported in annual reports

“On December 31, 2025, 69 of our employees were located in Israel, 4 were located in the United States and 2 employees were located in Europe; on December 31, 2024, 66 of our employees were located in Israel, 5 were located in the United States and 3 employees were located in Europe, and on December 31, 2023, 58 of our employees were located in Israel, 7 were located in the United States and 3 employees were located in”

See a number that looks wrong?